China Gas plans $1 5 billion share sale for gas projects, business development marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
China Gas plans $1.5b share sale for new gas projects, business development
FILE PHOTO: Gas storage facilities owned by China Gas Holdings are seen at a refueling station for ships in Chongqing, China December 12, 2017. REUTERS/Chen Aizhu
April 22, 2021
China Gas Holdings Ltd plans the sale of HK$11.66 billion ($1.50 billion) worth of new shares to major shareholders, to raise capital for gas projects and expansion.
It plans to acquire city gas projects in China, and expand and develop liquefied petroleum gas and distribution heating businesses.
The gas services provider has agreed to sell 392 million new shares, or 6.99% of the enlarged share capital, to shareholders Beijing Enterprises Holdings Ltd and China Gas Group Ltd, it said in a filing to the Hong Kong bourse on Thursday.
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
Published: Feb 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company s proprietary Engineered Thymic Niche (ETN) platform. The financing will